Indications
Therapeutic Asset Ratings
6,302 results matching 1 filter
91,565
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Decitabine
Castration-Resistant Prostate Carcinoma
Roswell Park Cancer Institute
P1/2
CC
(46)
Decitabine
Non-Hodgkin Lymphoma
Chinese PLA General Hospital
P1/2
CC
(46)
Dostarlimab
Diffuse Intrinsic Pontine Glioma
GlaxoSmithKline
P1/2
CC
(46)
Dostarlimab
Liver And Intrahepatic Bile Duct Neoplasm
GlaxoSmithKline
P1/2
CC
(46)
Durvalumab
Fibrolamellar Hepatocellular Carcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
P1/2
CC
(46)
Durvalumab
Folliculotropic Mycosis Fungoides
City of Hope Medical Center
P1/2
CC
(46)
Durvalumab
Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma
City of Hope Medical Center
P1/2
CC
(46)
eb-701/ca9-nk
Nonpapillary Renal Cell Carcinoma
Beijing Biotech
P1/2
CC
(46)
Eb-Dtnb-Nk
Neuroblastoma
Beijing Biotech
P1/2
CC
(46)
Eb-G3B7-Nk Dual-Target Car-Nk Cells
Liver Cancer
Beijing Biotech
P1/2
CC
(46)
ec5026
Parkinson Disease
EicOsis Human Health Inc.
P1/2
CC
(46)
Egfr/B7H3 Car-T
Glioblastoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
P1/2
CC
(46)
Egfr Fpbmc
Malignant Pancreatic Neoplasm
University of Virginia
P1/2
CC
(46)
Elimusertib
Ewing Sarcoma
National Cancer Institute (NCI)
P1/2
CC
(46)
Elimusertib
Lymphoma
National Cancer Institute (NCI)
P1/2
CC
(46)
Elimusertib
Refractory Malignant Neoplasm
National Cancer Institute (NCI)
P1/2
CC
(46)
Elranatamab
Myelodysplastic Syndrome
CellCentric Ltd.
P1/2
CC
(46)
Enitociclib
Lymphoid Neoplasm
National Cancer Institute (NCI)
P1/2
CC
(46)
Entinostat
Head And Neck Cancer
National Cancer Institute (NCI)
P1/2
CC
(46)
Entinostat
Oropharyngeal Carcinoma
National Cancer Institute (NCI)
P1/2
CC
(46)
Enzalutamide
Diffuse Large B-Cell Lymphoma
Novartis Pharmaceuticals
P1/2
CC
(46)
Erfonrilimab
Malignant Pancreatic Neoplasm
Shanghai Zhongshan Hospital
P1/2
CC
(46)
Fosifloxuridine Nafalbenamide
Cancer
NuCana plc
P1/2
CC
(46)
Fruquintinib
Burkitt Lymphoma
Immunitas Therapeutics
P1/2
CC
(46)
Fruquintinib
Diffuse Large B-Cell Lymphoma
Immunitas Therapeutics
P1/2
CC
(46)
Showing 3201 to 3225 of 6,302 assets
Previous
Page 129 of 253
Next